(Press-News.org) SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
“HR-positive, HER2-negative is the most common type of breast cancer in the United States and we frequently need to decide whether or not adjuvant chemotherapy would be beneficial, and if so, what type of chemotherapy would be beneficial,” explained Nan Chen, MD, assistant professor of internal medicine at the University of Chicago Medicine, who presented the study. Chen said that while patients with this type of breast cancer generally receive either adjuvant taxane-based regimens or taxane- and anthracycline-based regimens, there is limited data to guide the use of more intensive chemotherapy via the addition of anthracyclines.
Chen and her colleagues analyzed data from the TAILORx trial to compare outcomes of patients with stage I/II, node-negative, HR-positive, HER2-negative breast cancer who received either taxane with anthracycline/cyclophosphamide and similar regimens (T-AC) or taxane with cyclophosphamide (TC) chemotherapy after surgery. Within the trial, the OncotypeDX test was used to help predict which patients might benefit from chemotherapy. This commonly used gene assay provides a recurrence score (RS) between 0 and 100, with lower scores indicating a smaller risk of recurrence and thus a less likely benefit from adjuvant chemotherapy relative to its side effects.
Patients with an RS between 11 and 25 were randomly assigned to receive endocrine therapy alone or endocrine therapy plus a chemotherapy regimen chosen by the physician, while those with an RS over 26 received endocrine therapy plus a chemotherapy regimen chosen by the physician. Out of 2,639 eligible cases, 2,197 patients received TC while 442 were treated with T-AC, which included one of three regimens: anthracycline with cyclophosphamide followed by taxane; concurrent anthracycline, cyclophosphamide, and docetaxel; or other anthracycline with taxane combinations.
After controlling for age, grade, tumor size, and estrogen/progesterone receptor status, the use of T-AC in patients with an RS 31 or greater and tumors 2 cm or greater was associated with improved survival outcomes after five years.
Among patients with an RS 31 or greater, compared with those who received TC, patients who received T-AC had a higher distant recurrence-free interval (90.7% vs. 96.1%), distant recurrence-free survival (89.5% vs. 95.4%), recurrence-free interval (89.1% vs. 94.1%), and a trend towards improved recurrence- free survival (87.9% vs. 93.4%) and overall survival at five years (93.1% vs. 97.3%).
The benefit of anthracycline therapy was also found to increase as the RS increased above 31, while no trend toward benefit was seen in patients with a score between 26 and 30.
Chen and colleagues found a similar benefit of anthracycline regimens in premenopausal and postmenopausal patients, which she said suggests that the effect is not due to the ovarian suppressive effects of anthracyclines.
“These results are in line with current clinical practice, where we give anthracyclines more readily in tumors biologically closer to triple-negative disease,” Chen said. “While most HR-positive, HER2-negative tumors do not have RS 31 or greater, many of the highest RS tumors may have less estrogen receptor expression, higher proliferation, and are closer along the spectrum towards triple-negative disease, a subset in which the benefit of anthracyclines has been much more clearly demonstrated.”
Chen added that while some of the secondary endpoints, such as distant recurrence-free survival, only increased for T-AC when the tumor was larger than 2 cm, the primary endpoint of distant recurrence-free interval increased with T-AC regardless of tumor size. She and her colleagues will continue to validate these findings and examine the use of anthracyclines in other patient groups.
“We believe that these findings have some implications for clinical care with caution,” Chen said. “Previous trials have shown the early benefit in recurrence reduction with anthracyclines may be offset by late risk of non-breast cancer deaths such as leukemia, so longer-term follow-up will be needed, and these risks should be discussed with patients before considering anthracycline-based chemotherapy.”
Limitations of this study include the fact this is a posthoc analysis of the TAILORx study, which was not specifically designed to evaluate the benefit of anthracyclines and could bias results. Additionally, the benefits of anthracyclines in lower-risk patients (RS 26-30) may have been difficult to measure because of the overall lower risk of recurrence in this population.
The study was supported by the National Cancer Institute of the National Institutes of Health, the Cancer Research Foundation, and the Lynn Sage Breast Cancer Foundation. Chen reports receiving consultant fees from Guardant Health, Daiichi Sankyo, Stemline Therapeutics, Seagen, AstraZeneca, and Novartis.
END
SAN ANTONIO – The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
As some of the lessons learned from this trial, investigators suggest beginning ctDNA testing during treatment rather than waiting for treatment completion as done in ZEST, and including patients with high- risk ...
SAN ANTONIO – A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
While the use of CDK4/6 inhibitors combined with endocrine therapy have significantly improved outcomes in patients with HR-positive, ...
COLUMBUS, Ohio – Researchers are shining a light on cancer cells’ energy centers – literally – to damage these power sources and trigger widespread cancer cell death.
In a new study, scientists combined strategies to deliver energy-disrupting gene therapy using nanoparticles manufactured to zero in only on cancer cells. Experiments showed the targeted therapy is effective at shrinking glioblastoma brain tumors and aggressive breast cancer tumors in mice.
The research team overcame a significant challenge to break ...
DALLAS, December 13, 2024 — The American Heart Association and Major League Baseball (MLB) brought cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) training to the League’s annual Winter Meetings held in Dallas this week. Attendees from all 30 Major League Clubs and many organizations across the baseball industry learned lifesaving skills needed to respond confidently and capably in the event of a cardiac emergency.
According to American Heart Association data, 9 out of ...
More than six million Americans are affected by Alzheimer’s disease, a form of dementia marked by accumulation of amyloid-β within the brain. Amyloid-β is a relatively small protein that forms toxic plaques in the brain contributing to the harmful effects of Alzheimer's disease. Another protein, hyperphosphorylated tau (pTau), also accumulates as toxic neurofibrillary tangles. Together, amyloid-β plaques and pTau tangles result in brain damage, neuroinflammation and ultimately brain death.
Gene expression studies have already identified ...
(Carlisle, Pa.) — A new study in the journal Scientific Reports offers a rare glimmer of hope in the face of climate change, suggesting glacial rivers and lakes may play a crucial role in mitigating the effects of methane, a powerful greenhouse gas that recent studies have shown emerging as glaciers melt in warming global temperatures.
This new study, led by Dickinson College Associate Professor of Environmental Studies Kristin Strock, looked at what happens when glaciers melt and release trapped methane, a potent greenhouse gas that contributes to climate change. Strock, a 2019 National Geographic Explorer, led an all-female team of researchers ...
Over the last decade, the global market for plant-based beverages has seen remarkable growth, with oat, almond, soy and rice drinks emerging as popular alternatives to cow’s milk in coffee and oatmeal during this time.
One of the likely reasons for millions of liters of plant-based drinks ending up in the shopping baskets of consumers is that their climate footprint is often lower than that of cow’s milk. But consumers would be mistaken if they considered plant-based beverages healthier than cow’s milk. This is highlighted in a new study conducted by the University of Copenhagen in collaboration with the University ...
A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed a comprehensive set of innovative genetic tools and mouse lines, called iFlpMosaics, designed to enhance the study of gene function and its implications in health and disease.
The groundbreaking study, led by Dr. Rui Benedito and published in Nature Methods, presents a pioneering approach that overcomes critical limitations of existing methods for generating genetic mosaics. These innovations will enable scientists to more accurately investigate the effects of somatic mutations on cellular biology and disease.
The study highlights the iFlpMosaics toolkit's utility across different experimental setups, ...
Philadelphia, December 13, 2024 – Researchers from Children’s Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform, which can be used to develop cancer treatments by either directly modifying immune cells or by creating proteins that help immune cells locate cancer cells. The findings were published today by the journal Nature ...
Also known as Virgo A or NGC 4486, M87 is the brightest object in the Virgo cluster of galaxies, the largest gravitationally bound type of structure in the universe. It came to fame in April 2019 after scientists from EHT released the first image of a black hole in its center. Led by the EHT multi wavelength working group, a study published in Astronomy and Astrophysics Journal presents the data from the second EHT observational campaign conducted in April 2018, involving over 25 terrestrial and orbital telescopes. The authors report the first observation of a high-energy gamma-ray flare in over a decade from the supermassive black hole M87, based on nearly ...
